Book chapter
Circulating Tumor Markers for Breast Cancer Management
Molecular Pathology of Breast Cancer, pp.207-218
Springer International Publishing
11/27/2016
DOI: 10.1007/978-3-319-41761-5_14
Abstract
Many patients with early stage cancers will go on to develop metastases. Blood based tests for circulating tumor markers can provide an invaluable minimally invasive method for assessing tumor and monitoring patients. Several markers are purported to be available for this purpose. These include some newer biomarkers such as tissue polypeptide antigens and serum autoantibodies against tumor associated antigens. In this chapter, we critically evaluate the available markers and describe their advantages and more importantly their limitations. A thorough review of the data available for these biomarkers leads us to conclude that sufficient evidence exists for the use of CEA, CA15-3, CA27.29 in metastatic breast cancers. However, none of the biomarkers are suitable for routine use in patients with early stage breast cancer. Novel blood based-biomarkers are urgently required to monitor patients with early stage breast cancer and predict the long-term outcomes.
Details
- Title: Subtitle
- Circulating Tumor Markers for Breast Cancer Management
- Creators
- Dhivya Prabhakar - Case Western Reserve UniversityLyndsay Harris - Case Western Reserve University
- Resource Type
- Book chapter
- Publication Details
- Molecular Pathology of Breast Cancer, pp.207-218
- Publisher
- Springer International Publishing; Cham
- DOI
- 10.1007/978-3-319-41761-5_14
- Language
- English
- Date published
- 11/27/2016
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984359585902771
Metrics
10 Record Views